<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01759446</url>
  </required_header>
  <id_info>
    <org_study_id>AP-ADF-301</org_study_id>
    <nct_id>NCT01759446</nct_id>
  </id_info>
  <brief_title>Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users</brief_title>
  <official_title>A Single-center, Randomized, Double-blind, Active- and Placebo Controlled, 5-way Crossover Study Assessing the Abuse Potential of Intranasally Administered VYCAVERT Tablets in Non-dependent Recreational Opioid Users.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acura Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acura Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the relative abuse potential of VYCAVERT (hydrocodone bitartrate and
      acetaminophen) compared to GENERIC H/A (hydrocodone bitartrate and acetaminophen) when
      crushed and administered intranasally to non dependent, recreational opioid users.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Emax - Maximum Drug Liking</measure>
    <time_frame>8 hours</time_frame>
    <description>&quot;Do you dislike or like the drug effect you are feeling now?&quot; The question is scored using a 100-point bipolar visual analog scale (VAS) anchored in the center with &quot;neither like nor dislike&quot; (score of 50), on the left with &quot;Strong Disliking&quot; (score of 0) and on the right with &quot;Strong Liking&quot; (score of 100). Maximum Score. Assessment were made at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dosing.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Placebo taken first</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo powder snorted with all other arms taken crossover therafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Generic H/A taken first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Generic hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vycavert taken first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vycavert hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Generic H/A plus i taken first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Generic hydrocodone/APAP 10/325mg plus additional inactive ingredients pulverized tablet snorted with all other arms taken crossover therafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Generic H/A plus p taken first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Generic hydrocodone/APAP 10/325mg plus one placebo pulverized tablet snorted with all other arms taken crossover therafter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo taken first</intervention_name>
    <description>Snorted in both nostrils within 5 minutes; 48 hours washout between doses</description>
    <arm_group_label>Placebo taken first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic H/A taken first</intervention_name>
    <description>Snorted in both nostrils within 5 minutes; 48 hours washout between doses</description>
    <arm_group_label>Generic H/A taken first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vycavert taken first</intervention_name>
    <description>Snorted in both nostrils within 5 minutes; 48 hours washout between doses</description>
    <arm_group_label>Vycavert taken first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic H/A plus i taken first</intervention_name>
    <description>Snorted in both nostrils within 5 minutes; 48 hours washout between doses</description>
    <arm_group_label>Generic H/A plus i taken first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic H/A plus p taken first</intervention_name>
    <description>Snorted in both nostrils within 5 minutes; 48 hours washout between doses</description>
    <arm_group_label>Generic H/A plus p taken first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
             Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12 lead ECG and clinical laboratory tests.

          2. Subject is a recreational opioid user who is NOT dependent on opioids based on
             Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision
             (DSM IV TR) criteria. A recreational opioid user is defined as a user of opioids for
             non medical purposes (i.e., for psychoactive effects) on at least 10 occasions within
             the last year and at least once in the 12 weeks before the Screening Visit (Visit 1).

          3. Subjects must have experience with intranasal opioid administration, defined as
             intranasal use on at least 3 occasions within the last year before Screening.

          4. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          5. Subject is able to speak, read, and understand English sufficiently to comprehend the
             nature of the study and to understand the informed consent form (ICF) and consent
             process.

          6. An informed consent document signed and dated by the subject.

          7. Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

             -

        Exclusion Criteria:

          1. Diagnosis of substance and/or alcohol dependence (excluding caffeine and nicotine), as
             assessed by the Investigator using the DSM IV TR criteria.

          2. Has participated in, is currently participating in, or is seeking treatment for
             substance and/or alcohol related disorders (excluding nicotine and caffeine).

          3. Has a positive urine drug screen (UDS) including tetrahydrocannabinol (THC) at
             Screening (Visit 1). NOTE: Subjects with an opioid positive or THC-positive UDS at
             Visit 1 may be re tested once on or before Visit 2 (Day 0). If the UDS re test is
             negative, the subject can proceed to Visit 2. A positive UDS at Visit 2 will exclude
             the subject from further participation, unless the UDS is THC-positive in which the
             subject can continue in the study at the discretion of the Investigator.

          4. Has a positive alcohol breath test at Screening. Positive results may be repeated
             and/or subjects re scheduled at the Investigator's discretion.

          5. Has any condition in which an opioid is contraindicated (e.g., significant respiratory
             depression, acute or severe bronchial asthma or hypercarbia, suspected of having
             paralytic ileus).

          6. Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynne Webster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lifetree Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <results_first_submitted>June 27, 2018</results_first_submitted>
  <results_first_submitted_qc>October 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2018</results_first_posted>
  <last_update_submitted>October 2, 2018</last_update_submitted>
  <last_update_submitted_qc>October 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>44 recreational drug users with snorting experience were enrolled with 40 completing-Crossover designed</recruitment_details>
      <pre_assignment_details>Each subject had to pass a blinded snorted drug discrimination phase to meet enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Taken First</title>
          <description>followed by all other drugs with 48 hours washout in between</description>
        </group>
        <group group_id="P2">
          <title>Generic H/A Taken First</title>
          <description>followed by all other drugs with 48 hours washout in between</description>
        </group>
        <group group_id="P3">
          <title>Vycavert Taken First</title>
          <description>followed by all other drugs with 48 hours washout in between</description>
        </group>
        <group group_id="P4">
          <title>Generic H/A Plus i Taken First</title>
          <description>followed by all other drugs with 48 hours washout in between</description>
        </group>
        <group group_id="P5">
          <title>Generic H/A Plus p Taken First</title>
          <description>followed by all other drugs with 48 hours washout in between</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Adult Recreational Snorting Drug Users who completed the study design per protocol</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Taken First</title>
          <description>followed by all other doses crossover</description>
        </group>
        <group group_id="B2">
          <title>Generic H/A Taken First</title>
          <description>followed by all other doses crossover</description>
        </group>
        <group group_id="B3">
          <title>Vycavert Taken First</title>
          <description>followed by all other doses crossover</description>
        </group>
        <group group_id="B4">
          <title>Generic H/A Plus i Taken First</title>
          <description>followed by all other doses crossover</description>
        </group>
        <group group_id="B5">
          <title>Generic H/A Plus p Taken First</title>
          <description>followed by all other doses crossover</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.4" spread="3.99"/>
                    <measurement group_id="B2" value="24.4" spread="3.99"/>
                    <measurement group_id="B3" value="24.4" spread="3.99"/>
                    <measurement group_id="B4" value="24.4" spread="3.99"/>
                    <measurement group_id="B5" value="24.4" spread="3.99"/>
                    <measurement group_id="B6" value="24.4" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Emax - Maximum Drug Liking</title>
        <description>&quot;Do you dislike or like the drug effect you are feeling now?&quot; The question is scored using a 100-point bipolar visual analog scale (VAS) anchored in the center with &quot;neither like nor dislike&quot; (score of 50), on the left with &quot;Strong Disliking&quot; (score of 0) and on the right with &quot;Strong Liking&quot; (score of 100). Maximum Score. Assessment were made at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dosing.</description>
        <time_frame>8 hours</time_frame>
        <population>Completers of all doses per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Generic H/A</title>
            <description>Hydrocodone and Acetaminophen</description>
          </group>
          <group group_id="O3">
            <title>Vycavert</title>
            <description>hydrocodone and acetaminophen</description>
          </group>
          <group group_id="O4">
            <title>Generic H/A Plus i</title>
            <description>Hydrocodone/Acetaminophen with selected inactives</description>
          </group>
          <group group_id="O5">
            <title>Generic H/A Plus p</title>
            <description>Hydrocodone/Acetaminophen plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Emax - Maximum Drug Liking</title>
          <description>&quot;Do you dislike or like the drug effect you are feeling now?&quot; The question is scored using a 100-point bipolar visual analog scale (VAS) anchored in the center with &quot;neither like nor dislike&quot; (score of 50), on the left with &quot;Strong Disliking&quot; (score of 0) and on the right with &quot;Strong Liking&quot; (score of 100). Maximum Score. Assessment were made at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dosing.</description>
          <population>Completers of all doses per protocol</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" spread="8.52"/>
                    <measurement group_id="O2" value="75.0" spread="11.81"/>
                    <measurement group_id="O3" value="72.1" spread="12.98"/>
                    <measurement group_id="O4" value="75.6" spread="12.48"/>
                    <measurement group_id="O5" value="73.0" spread="13.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE's were collected as observed at systemically at pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5 and 24 hours post-dose. AE's were observed and reported from first dose through the end of study (11 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Generic H/A</title>
          <description>Hydrocodone and Acetaminophen</description>
        </group>
        <group group_id="E3">
          <title>Vycavert</title>
          <description>hydrocodone and acetaminophen</description>
        </group>
        <group group_id="E4">
          <title>Generic H/A Plus i</title>
          <description>Hydrocodone/Acetaminophen with selected inactives</description>
        </group>
        <group group_id="E5">
          <title>Generic H/A Plus p</title>
          <description>Hydrocodone/Acetaminophen plus placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Burning in throat</sub_title>
                <description>Burning in nasal &amp; throat</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="44"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nasal Burning</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E4" events="18" subjects_affected="18" subjects_at_risk="44"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Al Brzeczko</name_or_title>
      <organization>Acura Pharma</organization>
      <phone>847-705-7709</phone>
      <email>abrzeczko@acurapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

